The U.S. Food and Drug Administration (FDA) has greenlit an expanded access program (EAP) for Ascendis Pharma to allow certain adults with hypoparathyroidism to receive TransCon PTH, an investigational parathyroid hormone (PTH) replacement therapy. An EAP allows patients with life-threatening or serious diseases access to investigational therapies…
People who go on to develop hypoparathyroidism after surgery in the neck feel more tired and have less energy than control patients who do not develop the disease, a study from the U.K. has found. However, fatigue and low energy do not appear to reduce overall quality of life,…
Hypoparathyroidism was associated with hypertrophic cardiomyopathy — heart disease marked by thickened heart muscle, so that the heart pumps blood less effectively — in a 73-year-old woman, according to a case study. This rare finding was reported in “Hypertrophic cardiomyopathy in a patient with secondary hypoparathyroidism:…
Ascendis Pharma is seeking approval of its treatment candidate TransCon PTH for adults with hypoparathyroidism in the European Union, the company has announced. The request, submitted as a marketing authorization application (MAA) to the European Medicines Agency (EMA), follows a similar application submitted in September to the U.S.
Most experts report similar practices for how they monitor blood and urine tests in people with chronic hypoparathyroidism, but monitoring practices for disease complications like kidney or bone problems are more variable, a new study reports. “While [blood] and urine measurements are completed consistent with published guidelines and consensus…
Less experienced surgeons and removing lymph nodes in the neck during thyroid surgery are the main risk factors of accidentally damaging the neighboring parathyroid glands, which can cause hypoparathyroidism, a large study in China showed. A surgeon’s inexperience and a more advanced thyroid tumor also increased the risk of…
People with hypoparathyroidism who are on replacement therapy with Natpara, a version of the parathyroid hormone (PTH), are about half as likely to develop chronic kidney disease than patients who don’t receive the therapy, a study found. The study, “The risk of chronic kidney disease development in…
Daily treatment with AZP-3601, Amolyt Pharma’s experimental therapy for hypoparathyroidism, safely and effectively normalizes calcium levels in people with the disease, according to data from the second group of patients in a proof-of-concept Phase 2a clinical trial. Most participants stopped calcium and vitamin D supplements, which is the…
A Phase 1 clinical trial evaluating the safety and pharmacological properties of MBX 2109 — MBX Biosciences’ investigational hormone replacement therapy for people with hypoparathyroidism — in healthy volunteers has moved to its second part. This portion, which will test multiple MBX 2109 doses, follows the successful completion…
Parathyroid hormone (PTH) replacement therapy is superior to conventional treatment at lowering blood phosphate levels and the need for calcium and vitamin D supplements in people with chronic hypoparathyroidism, according to a review of clinical trial data. It appeared to be associated with higher-than-normal calcium levels (hypercalcemia) and had…
Get regular updates to your inbox.
